Latest news with #Insulet
Associated Press
5 days ago
- Business
- Associated Press
Kion Unveils New FinOps Governance Capabilities and Partnership with ProsperOps to Help Customers Maximize Cloud Value
SAN DIEGO--(BUSINESS WIRE)--Jun 3, 2025-- FinOps X — Kion, the leading automated CloudOps platform for multicloud, today announced the release of Kion version 3.13 alongside a new partnership with ProsperOps, a leading FinOps optimization platform. Through the partnership with ProsperOps and new Kion FinOps governance platform upgrades, Kion helps organizations simplify spend and budgets for faster decision making, apply usage policies to prevent cloud waste and automate FinOps governance and policy to drive efficiency across multicloud infrastructure. Kion v3.13 offers new features that provide better chargeback capabilities, a revamped dashboard experience, more powerful enforcements and additional user driven enhancements that make the platform easier to use and deliver value faster. These enhancements provide CloudOps and FinOps teams with more control over spend, enables faster anomaly detection and delivers a streamlined user experience. One of the company's newest customers, Insulet, the innovative medical device manufacturer of the Omnipod® insulin delivery platform, highlighted their reasons for selecting Kion: 'We needed a governance tool that could go beyond generic FinOps capabilities and provide clear, actionable insight into cloud spend so we could drive accountability across teams. Kion came at the perfect time, delivering a single workflow with forecasting and budgeting capabilities. It immediately helped surface waste and cost anomalies that used to take days to track down and shifted the conversation from reactive to proactive, automated cost control,' said Matt Cofran, Director of Cloud Operations, Insulet. 'FinOps governance and waste reduction are top priorities for businesses. Yet, cloud cost optimization is still a major challenge largely due to a lack of visibility, understanding and allocation of cloud resources and usage,' said David Roldan, Head of Partnerships and Alliances at ProsperOps. 'By partnering with Kion, we're able to bridge the FinOps and CloudOps gap, bringing together the best of both worlds — the automation for cloud cost savings with the policy driven governance that teams need to run efficiently and confidently in the cloud.' 'We say that the future of FinOps is CloudOps because of the rising priority of FinOps governance and policy at scale. A robust cloud operations platform will enable both teams to work together to manage their multicloud environment without spinning up unintentional resources or running over budget,' said Tatum Tummins, Senior Product Manager at Kion. 'Kion is well positioned to support the future of FinOps by forging fruitful partnerships and advancing our FinOps governance and automation capabilities to help regulated organizations maximize cloud value and deliver AI innovation faster.' Kion was recently recognized as an IDC Innovator for FinOps and Cloud Cost Transparency. According to the report, 'Kion was chosen as an innovator in the marketplace because of its commitment to supporting the growing and evolving cloud market.' The report notes Kion's key differentiators as; comprehensive cloud governance to help companies rapidly mature their FinOps teams, visibility and advanced automation and customer service. In addition to exhibiting at FinOps X, Kion will be exhibiting at AWS Summit, Washington DC on June 10-11. Stop by Kion's booth #348 to learn more about common CloudOps challenges, benefits of integrating FinOps into your CloudOps practices and new Kion capabilities that drive cloud efficiency for public sector IT leaders. Tummins will also be onsite for a Lightning Talk on Tuesday, June 10 at 2:35pm ET in the Apollo Theater covering 'FinOps ROI Playbook: Do More with Less to Maximize Cloud Efficiency.' View source version on CONTACT: Media Contact Natalie Sasscer 301-751-5176 LaunchTech Communications [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA DISTRICT OF COLUMBIA INDUSTRY KEYWORD: SOFTWARE MOBILE/WIRELESS NETWORKS PROFESSIONAL SERVICES PERSONAL FINANCE DATA MANAGEMENT APPS/APPLICATIONS TECHNOLOGY SECURITY ONLINE PRIVACY OTHER PROFESSIONAL SERVICES FINANCE OTHER TECHNOLOGY SOURCE: Kion Copyright Business Wire 2025. PUB: 06/03/2025 02:26 PM/DISC: 06/03/2025 02:25 PM
Business Wire
5 days ago
- Business
- Business Wire
Kion Unveils New FinOps Governance Capabilities and Partnership with ProsperOps to Help Customers Maximize Cloud Value
SAN DIEGO--(BUSINESS WIRE)-- FinOps X — Kion, the leading automated CloudOps platform for multicloud, today announced the release of Kion version 3.13 alongside a new partnership with ProsperOps, a leading FinOps optimization platform. Through the partnership with ProsperOps and new Kion FinOps governance platform upgrades, Kion helps organizations simplify spend and budgets for faster decision making, apply usage policies to prevent cloud waste and automate FinOps governance and policy to drive efficiency across multicloud infrastructure. Kion v3.13 offers new features that provide better chargeback capabilities, a revamped dashboard experience, more powerful enforcements and additional user driven enhancements that make the platform easier to use and deliver value faster. These enhancements provide CloudOps and FinOps teams with more control over spend, enables faster anomaly detection and delivers a streamlined user experience. One of the company's newest customers, Insulet, the innovative medical device manufacturer of the Omnipod® insulin delivery platform, highlighted their reasons for selecting Kion: 'We needed a governance tool that could go beyond generic FinOps capabilities and provide clear, actionable insight into cloud spend so we could drive accountability across teams. Kion came at the perfect time, delivering a single workflow with forecasting and budgeting capabilities. It immediately helped surface waste and cost anomalies that used to take days to track down and shifted the conversation from reactive to proactive, automated cost control,' said Matt Cofran, Director of Cloud Operations, Insulet. Meeting the Needs of Regulated Enterprises As a self-hosted platform, Kion is uniquely suited for government agencies and enterprises with complex compliance, data sovereignty and regulation requirements. The partnership with ProsperOps allows FinOps teams to shift from reactive cost control to strategic financial operations. Kion unifies governance, automation and FinOps in a policy-based platform that works with ProsperOps automation, integrating rate and workload optimization to reduce risks, cloud costs and manual effort. Together, the two platforms provide a well-rounded efficiency solution that is advantageous to government agencies and highly regulated industries seeking FinOps optimization controls while also needing to streamline compliance with stringent federal security and operational requirements. 'FinOps governance and waste reduction are top priorities for businesses. Yet, cloud cost optimization is still a major challenge largely due to a lack of visibility, understanding and allocation of cloud resources and usage,' said David Roldan, Head of Partnerships and Alliances at ProsperOps. 'By partnering with Kion, we're able to bridge the FinOps and CloudOps gap, bringing together the best of both worlds — the automation for cloud cost savings with the policy driven governance that teams need to run efficiently and confidently in the cloud.' "We say that the future of FinOps is CloudOps because of the rising priority of FinOps governance and policy at scale. A robust cloud operations platform will enable both teams to work together to manage their multicloud environment without spinning up unintentional resources or running over budget,' said Tatum Tummins, Senior Product Manager at Kion. 'Kion is well positioned to support the future of FinOps by forging fruitful partnerships and advancing our FinOps governance and automation capabilities to help regulated organizations maximize cloud value and deliver AI innovation faster.' Kion was recently recognized as an IDC Innovator for FinOps and Cloud Cost Transparency. According to the report, 'Kion was chosen as an innovator in the marketplace because of its commitment to supporting the growing and evolving cloud market.' The report notes Kion's key differentiators as; comprehensive cloud governance to help companies rapidly mature their FinOps teams, visibility and advanced automation and customer service. In addition to exhibiting at FinOps X, Kion will be exhibiting at AWS Summit, Washington DC on June 10-11. Stop by Kion's booth #348 to learn more about common CloudOps challenges, benefits of integrating FinOps into your CloudOps practices and new Kion capabilities that drive cloud efficiency for public sector IT leaders. Tummins will also be onsite for a Lightning Talk on Tuesday, June 10 at 2:35pm ET in the Apollo Theater covering 'FinOps ROI Playbook: Do More with Less to Maximize Cloud Efficiency.' About Kion Kion automates CloudOps with a single platform providing policy-based identity, FinOps, and compliance for multicloud infrastructure. Kion helps organizations achieve 'governance by default' through improved visibility, automation, guardrails, and guidance across multicloud environments. This helps enterprises reduce complexity, eliminate chaos, and minimize manual work so they can innovate faster with less risk. Wherever they are on their cloud journey, Kion empowers organizations to confidently provision accounts, maintain financial control, and ensure compliance with security regulations. Kion serves leading commercial, higher education, and government agencies including Indeed, Verizon, NASA, and the Centers for Disease Control and Prevention (CDC).
Yahoo
30-05-2025
- Business
- Yahoo
Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy
-- Goldman Sachs has initiated coverage of diabetes technology stocks Insulet (NASDAQ:PODD) and Dexcom (NASDAQ:DXCM) with Buy ratings, citing strong long-term growth prospects in both the insulin delivery and continuous glucose monitoring (CGM) markets. In a research note, Goldman Sachs described the diabetes technology market as 'at a crossroads,' with growth shifting from its core Type 1 diabetes patient base toward the broader Type 2 diabetes population and even consumer markets. 'We see Insulet as well positioned to accelerate market share capture given its unique form factor (patch vs durable), pharmacy access, and Type 2 indication,' the analysts wrote. They added that the company's valuation sits 'at the high end of growth medtech.' Dexcom also earned a Buy rating, with Goldman noting that while the stock has underperformed over the past year, falling 43% relative to the S&P 500, 'we view forward estimates as appropriately re-calibrated.' The analysts expect 'upside to 2025 top-line expectations,' though they acknowledged caution on gross margins due to 'supply-related issues in 1H.' Still, they believe 'more steady execution should unlock share value from here.' Goldman sees the insulin pump market growing 11.4% annually in volume and 12.7% in dollars through 2028, driven by further penetration into the Type 1 population and expansion into the Type 2 multiple daily injector segment. 'We expect patch pump technology to become the primary form factor for insulin pumps,' the firm said, projecting a shift from 30% patch pump share in 2024 to 40% by 2028. Goldman also initiated coverage on Beta Bionics (BBNX) with a Neutral rating and maintained existing ratings on Abbott (ABT, Buy) and Tandem (TNDM, Neutral). Related articles Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy AGCO downgraded as Citi says risk/reward now more balanced Sanofi, Regeneron shares nosedive after mixed Itepekimab results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
30-05-2025
- Business
- Business Insider
Insulet initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Insulet (PODD) with a Buy rating and $380 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Insulet stands to benefit from accelerating adoption of patch pump technology with the company being the only participant in the category today, the analyst tells investors in a research note. The company's pipeline also offers the potential to further strengthen its relative position, while its sustained top-line growth should support outsized adjusted EBITDA results, Goldman Sachs added. Confident Investing Starts Here:
Associated Press
23-05-2025
- Business
- Associated Press
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--May 23, 2025-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. View source version on CONTACT: Investor Relations: June Lazaroff Senior Director, Investor Relations (978) 600-7718 [email protected]: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: DIABETES HEALTH MEDICAL DEVICES SOURCE: Insulet Corporation Copyright Business Wire 2025. PUB: 05/23/2025 06:01 AM/DISC: 05/23/2025 06:01 AM
